2024-513867-19-00招募中3 期
DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 285
- 试验地点
- 24
- 主要终点
- The OS comparison between treatments will be evaluated at each interim analysis and the final analysis using the stratified logrank test. The stratification factors are: 1. Prior docetaxel for castration-sensitive disease (Yes or No) 2. Visceral disease (presence or absence)
研究概览
简要总结
Compare overall survival for subjects treated with docetaxel versus subjects treated with docetaxel plus Radium-223
研究设计
- 分配方式
- Not Applicable
- 主要目的
- Screening period
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide, or have a legally authorized representative provide, written informed consent (ICF) and HIPAA authorization for the release of personal health information. A signed ICF must be obtained before screening procedures are performed. NOTE: HIPAA authorization may be either included in the ICF or obtained separately
- •All acute toxic effects of any prior treatment have resolved to NCI-CTCAE v4.0 Grade 1 or less
- •Willing and able to comply with the protocol, including follow-up visits and examinations
- •Males 18 years of age and abov
- •Histological or cytological proof of prostate cancer
- •Documented progressive mCRPC based on at least one of the following criteria: a) PSA progression defined as a minimum of 2 rising PSA levels with a minimum of a 1 week interval between each determination. A minimum PSA of 1.0 ng/mL is required for study entry. b) Soft-tissue progression defined as an increase ≥ 20% in the sum of the longest diameter (LD) of all target lesions based on the smallest sum LD since treatment started or the appearance of one or more new lesions. c) Progression of bone disease (evaluable disease) by two or more new bone lesions by bone scan
- •Two or more bone lesions defined by nuclear bone scan
- •ECOG of 0 or 1 (Appendix A: Performance Status Criteria)
- •Normal organ function with acceptable initial laboratory values within 14 days of randomization
- •Subjects must agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including 6 months after the last dose of study drug. Sperm donation is prohibited during the study and for 6 months after the last dose of study drug. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent
- •Serum testosterone < 50 ng/dL. Subjects must continue primary androgen deprivation with an LHRH analogue (agonist or antagonist) if they have not undergone orchiectomy
排除标准
- •Received any other investigational therapeutic agents or other anticancer therapies within 2 weeks or 5 half-lives, whichever is shorter, prior to randomization. Note: If this requirement to have a washout of 2 weeks or 5 half-lives prior to randomization causes potential treatment delay due to Radium-223 importation timelines, the PCCTC must be contacted to request approval to randomize the subject prior to the completion of the washout. Requests for early randomization must be accompanied by written assurance by the site that the washout will be completed prior to treatment start.
- •Symptomatic nodal disease (i.e., scrotal, penile, or leg edema)
- •Has visceral metastases with > 3 lung and/or liver metastases or individual lesion >2 cm, as assessed by CT scan or MRI of the chest/abdomen/pelvis within the last 8 weeks prior to randomization
- •Symptomatic loco-regional disease that causes ongoing Grade 3 or Grade 4 urinary or rectal symptoms
- •Subjects with a second malignancy with a risk of recurrence >30% within the next 3 years. Non-melanoma skin cancers, non-invasive bladder cancers, and other in-situ or non-invasive malignancies are permitted while on study
- •Has imminent or established cord compression based on clinical findings and/or MRI
- •Known bone marrow dysplasia
- •Has received any of the following in the 4 weeks prior to randomization: 5-alphareductase inhibitors, natural hormonally active foods (e.g., phytoestrogens) or other food supplements known to alter PSA in humans
- •Is receiving ongoing treatment with herbal medications that are known in humans to alter PSA or the natural history of prostate cancer. Subjects must discontinue any such herbal medications prior to the first dose of study drug
- •Any other serious illness or medical condition that would, in the opinion of the Investigator, make this protocol unreasonably hazardous, including but not limited to: • Uncontrolled infection • NYHA III or IV heart failure • Crohn’s disease or those with ulcerative colitis who have not undergone a colectomy • Known active infection with HIV, Hepatitis B or Hepatitis C
- •Received external beam radiotherapy (EBRT) within the 2 weeks prior to randomization. Note: If prolonging randomization to complete EBRT washout causes potential treatment delay due to Radium-223 importation timelines, the PCCTC must be contacted to request approval to randomize the subject prior to the completion of the washout. Requests for early randomization must be accompanied by written assurance by the site that the washout will be completed prior to treatment start
- •Has an immediate need for EBRT.
- •Has received any other systemic investigational or anti-cancer radiopharmaceutical in the past
- •Has received any prostate cancer directed chemotherapy in the castration resistant setting
- •Has received > 6 prior doses of docetaxel in the castration sensitive setting. Subjects who have received up to 6 prior doses of docetaxel in the castration sensitive setting are permitted if they have not experienced disease progression within 36 weeks of last treatment with docetaxel
- •Has received four or more systemic anticancer regimens for mCRPC
- •Has known Grade ≥3 non-hematological docetaxel-related toxicities or docetaxel toxicity related dose interruption or discontinuation
- •Has received blood transfusions or growth factors within the last 4 weeks prior to randomization.
结局指标
主要结局
The OS comparison between treatments will be evaluated at each interim analysis and the final analysis using the stratified logrank test. The stratification factors are: 1. Prior docetaxel for castration-sensitive disease (Yes or No) 2. Visceral disease (presence or absence)
The OS comparison between treatments will be evaluated at each interim analysis and the final analysis using the stratified logrank test. The stratification factors are: 1. Prior docetaxel for castration-sensitive disease (Yes or No) 2. Visceral disease (presence or absence)
次要结局
- Time to event endpoints will be analyzed using a stratified logrank test with the same stratification factors. Kaplan-Meier estimates of SSE-free survival and radiographic PFS will be computed. The cumulative incidence function will be used to compute probabilities for the time to first skeletal related event and the time to ALP progression. All time to event probability estimates will be calculated within treatment.
- Total ALP response will be compared between the treatment groups using a CMH test adjusting for the randomization strata
- Time to maximum % post-therapy decrease in PSA will be summarized using descriptive statistics
- Maximum % decrease in PSA will be summarized using descriptive statistics (e.g., mean, standard deviation, median, minimum, and maximum)
- Longitudinal kernel smoothing methods will be used to estimate the PSA, bone marker, BSI, CTC, and ctDNA trajectories over time. Joint modeling will used to evaluate these trajectories with respect to OS
- PROs will include scores from the QOL questionnaires: FACT-P, BPI, and BFI. The QOLs will be administered at baseline, week 19, Safety Follow Up, and Follow Up visits every 3 months for 1 year from last dose of either study drug. The scorespecific area under the curve (with respect to time) will be derived for each subject and these area-under-curve (AUCs) will be compared between treatments.
- The number and percentage of febrile neutropenia in subjects treated with docetaxel plus Radium-223
- The percentage of treatment discontinuation in subjects who are on their fourth line of therapy will be calculated by treatment arm and total
研究者
Michael J. Morris
Scientific
Memorial Sloan Kettering Cancer Center
研究点 (24)
Loading locations...
相似试验
招募中
3 期
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.2023-509340-10-00OSE Immunotherapeutics289
已完成
2 期
MK-7684A (new drug co-formulation of pembrolizumab with an anti-TIGIT) plus docetaxel works to help stop or slow down the growth of your non-small cell lung cancer (NSCLC) compared to docetaxel alone2022-501252-28-00Merck Sharp & Dohme LLC150
招募中
3 期
Phase 3 Study of I-DXd Versus Docetaxel in mCRPC2024-517423-40-00Merck Sharp & Dohme LLC508
招募中
2 期
Safety and preliminary effectiveness of BNT327, an investigational therapy for patients with non-small cell lung cancer in combination with chemotherapy following chemoimmunotherapyNon-small Cell Lung Cancer2024-518279-80-00BioNTech SE10
招募中
3 期
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)10038597prostate cancerNL-OMON54758Memorial Sloan Kettering Cancer Center250